Bromo-Cyclobutenaminones as New Covalent UDP-<i>N</i>-Acetylglucosamine Enolpyruvyl Transferase (MurA) Inhibitors

Drug discovery programs against the antibacterial target UDP-<i>N</i>-acetylglucosamine enolpyruvyl transferase (MurA) have already resulted in covalent inhibitors having small three- and five-membered heterocyclic rings. In the current study, the reactivity of four-membered rings was ca...

Full description

Bibliographic Details
Main Authors: David J. Hamilton, Péter Ábrányi-Balogh, Aaron Keeley, László Petri, Martina Hrast, Tímea Imre, Maikel Wijtmans, Stanislav Gobec, Iwan J. P. de Esch, György Miklós Keserű
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/13/11/362
Description
Summary:Drug discovery programs against the antibacterial target UDP-<i>N</i>-acetylglucosamine enolpyruvyl transferase (MurA) have already resulted in covalent inhibitors having small three- and five-membered heterocyclic rings. In the current study, the reactivity of four-membered rings was carefully modulated to obtain a novel family of covalent MurA inhibitors. Screening a small library of cyclobutenone derivatives led to the identification of bromo-cyclobutenaminones as new electrophilic warheads. The electrophilic reactivity and cysteine specificity have been determined in a glutathione (GSH) and an oligopeptide assay, respectively. Investigating the structure-activity relationship for MurA suggests a crucial role for the bromine atom in the ligand. In addition, MS/MS experiments have proven the covalent labelling of MurA at Cys115 and the observed loss of the bromine atom suggests a net nucleophilic substitution as the covalent reaction. This new set of compounds might be considered as a viable chemical starting point for the discovery of new MurA inhibitors.
ISSN:1424-8247